Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
{{output}}
Background: Sacituzumab govitecan is an antibody-drug conjugate that is FDA approved for refractory metastatic triple-negative breast cancer. It targets the human trophoblastic cell-surface antigen 2 (Trop-2) with SN-38, a topois... ...
